Syros Pharmaceuticals Inc (NASDAQ:SYRS) insider Jeremy P. Springhorn purchased 9,879 shares of the business’s stock in a transaction on Monday, November 11th. The shares were purchased at an average price of $4.99 per share, with a total value of $49,296.21. Following the completion of the purchase, the insider now owns 24,879 shares in the company, valued at $124,146.21. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink.
Shares of NASDAQ:SYRS opened at $5.24 on Thursday. The stock has a 50 day moving average of $7.30 and a 200 day moving average of $7.96. The company has a market cap of $211.77 million, a PE ratio of -2.74 and a beta of 1.49. The company has a current ratio of 8.11, a quick ratio of 8.11 and a debt-to-equity ratio of 0.15. Syros Pharmaceuticals Inc has a 12-month low of $4.88 and a 12-month high of $11.93.
Syros Pharmaceuticals (NASDAQ:SYRS) last announced its quarterly earnings data on Tuesday, November 12th. The company reported ($0.47) earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($0.48) by $0.01. Syros Pharmaceuticals had a negative return on equity of 79.79% and a negative net margin of 3,137.55%. The company had revenue of $0.56 million during the quarter, compared to the consensus estimate of $0.43 million. Equities research analysts predict that Syros Pharmaceuticals Inc will post -1.88 earnings per share for the current fiscal year.
A number of equities research analysts have issued reports on SYRS shares. Cowen restated a “buy” rating on shares of Syros Pharmaceuticals in a research note on Tuesday. Zacks Investment Research upgraded Syros Pharmaceuticals from a “hold” rating to a “buy” rating and set a $7.25 price objective for the company in a research note on Wednesday, October 23rd. BidaskClub upgraded Syros Pharmaceuticals from a “hold” rating to a “buy” rating in a research note on Friday, October 18th. HC Wainwright reiterated a “hold” rating and set a $10.00 price objective on shares of Syros Pharmaceuticals in a research note on Wednesday. Finally, ValuEngine upgraded Syros Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Thursday, October 17th. Two investment analysts have rated the stock with a hold rating and eight have issued a buy rating to the company. The company currently has an average rating of “Buy” and a consensus price target of $13.46.
Syros Pharmaceuticals Company Profile
Syros Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development of treatment for cancer and monogenic diseases, and building a pipeline of gene control medicines. Its lead product candidates include SY-1425, a selective retinoic acid receptor alpha agonist, which is in a Phase II clinical trial for genomically defined subsets of patients with acute myeloid leukemia (AML) and myelodysplastic syndrome; SY-1365, a selective cyclin-dependent kinase 7 (CDK7) inhibitor, which is in a Phase I clinical trial that is used for treating patients with solid tumors and blood cancers, including ovarian and breast cancer; and SY-5609, a CDK7 inhibitor, which is in preclinical studies to treat oncology patients.
See Also: Which market index is the best?
Receive News & Ratings for Syros Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Syros Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.